Top 4 NYSE Stocks In The Biotechnology Industry With The Highest Revenue Estimates

Below are the top biotechnology stocks on the NYSE in terms of revenue estimate for the current year. Analysts expect Charles River Laboratories International

to post revenue of $1.14 billion for the year ending December, 2012. Charles River Laboratories' trailing-twelve-month ROE is 17.83%. Emergent BioSolutions

is expected to report revenue of $286.38 million for the year ending December, 2012. Emergent BioSolutions' PEG ratio is 0.72. Cambrex

is likely to post revenue of $274.60 million in the year ending December, 2012. Cambrex's trailing-twelve-month operating margin is 12.83%. ShangPharma

may report revenue of $132.94 million in the year ending December, 2012. ShangPharma had $34.74 million in total cash for the recent quarter.